



**LEGISLATIVE FISCAL OFFICE  
Fiscal Note**

Fiscal Note On: **HB 316** HLS 21RS 380  
 Bill Text Version: **REENGROSSED**  
 Opp. Chamb. Action: **w/ SEN COMM AMD**  
 Proposed Amd.:  
 Sub. Bill For.:

<b>Date:</b> June 4, 2021	1:31 PM	<b>Author:</b> DAVIS
<b>Dept./Agy.:</b> LDH/OPH		
<b>Subject:</b> Newborn screening panel		<b>Analyst:</b> Tanesha Morgan

CHILDREN/NEWBORNS RE1 +\$187,717 GF EX See Note Page 1 of 1  
 Adds mucopolysaccharidosis type I and glycogen storage disorder type II to the state's newborn screening panel

Proposed law provides that mucopolysaccharidosis type I (MPS I) and glycogen storage disorder type II (Pompe) diseases shall be added to the list of genetic conditions for which newborn children are tested.

This Act shall become effective on January 1, 2022.

EXPENDITURES	<u>2021-22</u>	<u>2022-23</u>	<u>2023-24</u>	<u>2024-25</u>	<u>2025-26</u>	<u>5 -YEAR TOTAL</u>
State Gen. Fd.	\$187,717	\$375,434	\$375,434	\$375,434	\$375,434	<b>\$1,689,453</b>
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$252,533	\$505,066	\$505,066	\$505,066	\$505,066	<b>\$2,272,797</b>
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<b>\$0</b>
<b>Annual Total</b>	<b>\$440,250</b>	<b>\$880,500</b>	<b>\$880,500</b>	<b>\$880,500</b>	<b>\$880,500</b>	<b>\$3,962,250</b>
REVENUES	<u>2021-22</u>	<u>2022-23</u>	<u>2023-24</u>	<u>2024-25</u>	<u>2025-26</u>	<u>5 -YEAR TOTAL</u>
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Agy. Self-Gen.	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Ded./Other	\$0	\$0	\$0	\$0	\$0	<b>\$0</b>
Federal Funds	\$252,533	\$505,066	\$505,066	\$505,066	\$505,066	<b>\$2,272,797</b>
Local Funds	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<u>\$0</u>	<b>\$0</b>
<b>Annual Total</b>	<b>\$252,533</b>	<b>\$505,066</b>	<b>\$505,066</b>	<b>\$505,066</b>	<b>\$505,066</b>	<b>\$2,272,797</b>

**EXPENDITURE EXPLANATION**

The proposed legislation is anticipated to increase expenditures in OPH by \$440,250 for testing (\$17.61 per test x 25,000 births for 6 months in FY 22) as a result of adding MPS I and Pompe diseases to the newborn screening panel. This cost will be annualized in future fiscal years. The OPH's Genetic Disease program and laboratory services would provide for screening, follow up, and surveillance activities to add MPS I and Pompe diseases to the screening panel.

OPH anticipates hiring a Laboratory Scientist and Program Monitor at a salary of \$63 K and \$72 K, respectively, plus related benefits to perform testing and follow up activities. The LFO cannot corroborate that the requirements of the proposed law will create a workload level sufficient to require two full time employees. To the extent that existing employees are used, personnel cost will be mitigated. Therefore, this cost is not reflected in the total above.

The fiscal note also does not anticipate any treatment cost associated with newborns that test positive for MPS I or Pompe disease.

NOTE: A portion of the testing cost will be reimbursed to OPH by the Medicaid program. The total reimbursement is anticipated to be \$355,680 which is calculated by multiplying the Medicaid reimbursement rate for the tests by the projected number of Medicaid eligible newborns (18,000 Medicaid newborns for 6 months in FY 22 x \$19.76 reimbursement rate for tests). The total reimbursement would represent an approximate 29% cost to DHH in state matching funds of \$103,147 and \$252,533 of federal funds. This cost will be annualized in future fiscal years.

**REVENUE EXPLANATION**

The proposed legislation adds MPS I and Pompe disease to the newborn screening panel, resulting in an increase in expenses that are eligible for reimbursement through Medicaid. The increase in federal revenue is anticipated to be \$252,533. See NOTE above. This revenue will be annualized in future fiscal years.

Senate  
 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}  
 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}

House  
 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}  
 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}

*Alan M. Boxberger*  
 Alan M. Boxberger  
 Staff Director